FDA approval brings first generic pergolide option for horses

Zygolide, a peppermint-flavored pergolide tablet from Dechra, entered the U.S. equine market after FDA approval as the first generic, bioequivalent alternative to Prascend for controlling clinical signs of pituitary pars intermedia dysfunction, or PPID, in horses. FDA announced the approval on January 9, 2026, and said Zygolide contains the same active ingredient as Prascend, which was first approved in 2011. Dechra positioned the product around practical administration features, including 360-degree scoring for half-tablet dosing and a flavor profile meant to support daily use in horses that need long-term therapy, while promotional materials in equine media framed the launch around helping owners “rediscover the partnership” and create “more happy moments together.” (fda.gov)

Why it matters: For equine veterinarians, the arrival of a generic pergolide option could ease one of the biggest friction points in PPID management: long-term adherence. PPID is common in older horses, and treatment often requires ongoing dose titration, monitoring of clinical signs, and endocrine testing. A lower-cost alternative with scored tablets may help some pet parents stay on therapy, especially in higher-dose cases, and Dechra’s owner-facing messaging clearly leans into quality-of-life and the horse-owner bond. The label also underscores familiar handling and safety issues, including not crushing tablets and using caution when splitting them because pergolide exposure can irritate people. (equimanagement.com)

What to watch: Watch for early field uptake, pricing pressure on pergolide therapy, and whether easier access to treatment pairs with broader PPID screening and monitoring efforts in 2026. It will also be worth watching whether Dechra’s lifestyle-oriented messaging translates into better refill persistence in a disease where daily administration is often the hard part. (equinefacilitydesign.com)